Evolving strategies for renoprotection: Diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 4, 2001, Pages 515-522

  Parving, Hans Henrik ^a   Hovind, Peter ^a   Rossing, Kasper ^a   Andersen, Steen ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; PROTEINURIA; REMISSION; RENAL PROTECTION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROTIC SYNDROME; PROGNOSIS; RECEPTORS, ANGIOTENSIN;

EID: 0034913098     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200107000-00006     Document Type: Review

References (79)

1. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
2. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients
3. Diabetic nephropathy
4. The causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy
5. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
6. Monitoring glomerular function in diabetic nephropathy
7. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy
8. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
9. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus
10. Diabetic nephropathy in type II diabetes
11. Diabetic nephropathy and arterial hypertension
12. The clinical course of diabetic nephropathy
13. Long term juvenile diabetes treated with unmeasured diet
14. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes
15. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
16. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
17. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
18. Use of enalapril to attennuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus
19. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study ad MICRO-HOPE substudy
20. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM
21. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
22. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
23. Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis
24. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
25. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus
26. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients
27. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria
28. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial
29. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
30. Intensive therapy and progressive to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria
31. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes
32. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
34. Reversal of lesions of diabetic nephropathy after pancreas transplantation
35. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
36. Effect of antihypertensive treatment on kidney function in diabetic nephropathy
37. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy
38. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
39. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy
40. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
41. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy
42. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy
43. Renal protective effect of enalapril in diabetic nephropathy
44. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
45. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy
46. Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients [abstract]
47. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
48. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
49. Long-term effect of lisinopril and atenolol on kidney function in hypertensive non-insulin-dependent diabetic subjects with diabetic nephropathy
50. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function
51. Albuminuria and poor glycemic control predicts mortality in NIDDM
52. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy
53. Predictors of mortality in insulin dependent diabetes: 10-year follow-up study
54. An economic analysis of captopril in the treatment of diabetic nephropathy
55. Progression of diabetic nephropathy
56. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
57. Is remission/regression of diabetic nephropathy possible?
58. Remission of nephrotic-range proteinuria in type I diabetes
59. Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the captopril study
60. Remission of nephrotic range albuminuria in diabetic nephropathy
61. Renoprotective effects of angiotensin II receptor blokade in type 1 diabetic patients with diabetic nephropathy
62. Optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy
63. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
64. Renoprotective effect of dual blockade of the renin-angiotensin system (RAS) in diabetic nephropathy
65. Protein glycation in the kidney: Role in diabetes and aging
66. An agent clearing glucose-derived protein crosslinks in vitro and in vivo
67. Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with type 1 diabetes mellitus (DM)
68. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor
69. Protein kinase C activation and the development of diabetic complications
70. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice
71. Administration of ascorbic acid and an aldose reductase inhibitor (Tolrestat) in diabetes: Effect on urinary albumin excretion
72. Renoprotective effect of combined treatment with vitamin C and E in type 2 diabetic patients with elevated urinary albumin excretion rate
73. Glycosaminoglycan therapy for long-term diabetic complications?
74. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
75. IGF-binding protein-related protein-2 (IGFBP-rP2) may play a role in proteinuria-accelerated interstitial fibrosis in diabetic nephropathy
76. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
77. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus
78. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats
79. Initiation and progression of diabetic nephropathy